Form 4: Candel Therapeutics CMO Executes Pre-Planned Stock Option Exercise and Sale

Candel Therapeutics' Chief Medical Officer, William Garrett Nichols, executed a pre-planned transaction involving the exercise of stock options and the subsequent sale of common stock on June 30, 2025, under a Rule 10b5-1 trading plan.

Summary

• William Garrett Nichols, Chief Medical Officer of Candel Therapeutics, Inc. (CADL), engaged in a pre-arranged stock transaction on June 30, 2025.
• The transaction involved the exercise of 781 stock options at an exercise price of $1.29 per share.
• Concurrently, 781 shares of common stock were sold at a price of $5.04 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 22, 2024.
• Following these transactions, Mr. Nichols beneficially owns 52,493 shares of common stock and 30,314 stock options.
• The stock options are subject to time-based vesting, with shares vesting in 48 equal monthly installments following April 28, 2023, contingent on continued service, and have an expiration date of April 28, 2033.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine, pre-planned insider stock option exercise and sale under a 10b5-1 plan, which is a common and expected event for executives managing their equity compensation. It does not indicate significant positive or negative news about the company's operations or future prospects.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating a pre-planned and transparent approach to insider trading.
• The exercise of stock options at $1.29 and subsequent sale at $5.04 indicates a profitable transaction for the insider, reflecting an increase in the stock price since the option grant.
• The Chief Medical Officer continues to hold a significant number of shares (52,493) and options (30,314), aligning his interests with shareholders.

Negatives

• The sale of 781 shares by a Chief Medical Officer, even if pre-planned, reduces his direct ownership stake in the company.

Future Outlook

NA

Management Comments

• This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

Industry Context

This is a routine insider transaction filing (Form 4) for a biotechnology company. Such filings are common across all industries for executives managing their equity compensation. The specific details relate to Candel Therapeutics, Inc., a company likely involved in therapeutic development, given the "Chief Medical Officer" role.

Comparison to Industry Standards

• This is a standard Form 4 filing, typical for executives managing equity compensation.
• The use of a 10b5-1 plan is a common and recommended practice for insiders to avoid accusations of trading on material non-public information, aligning with best practices for corporate governance in publicly traded companies, including those in the biotechnology sector.
• No specific comparable companies, projects, or results are mentioned in the document.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale, which might be viewed neutrally. The continued holding of shares and options by the CMO aligns his interests with shareholders. The sale at a higher price than the exercise price indicates a profitable transaction for the insider, which could be seen as a positive signal regarding the stock's performance.

Key Dates

Keywords

Candel Therapeutics, CADL, William Garrett Nichols, Chief Medical Officer, CMO, SEC Form 4, insider trading, stock option exercise, stock sale, 10b5-1 plan, beneficial ownership